Back to results
US 2003/0119765 A1Published application
MDM2-specific antisense oligonucleotides
AssigneeHybridon, Inc.
InventorsJiandong Chen, Sudhir Agrawal, Ruiwen Zhang
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeHybridon, Inc.
InventorsJiandong Chen, Sudhir Agrawal, Ruiwen Zhang
Estimating the term…
The invention provides methods to activate tumor suppressors. The invention further provides antisense oligonucleotides complementary to a portion of the MDM2-encoding RNA and methods for using such antisense oligonucleotides as analytical and diagnostic tools, as potentiators of transgenic animal studies and for gene therapy approaches, and as potential therapeutic agents. The invention also provides methods to augment and synergistically activate a tumor suppressor in conjunction with the use of a DNA-damage inducing agent. The invention further provides in vitro and in vivo models to evaluate the therapeutic effectiveness of a recently identified anti-human-MDM2 antisense oligonucleotide in the treatment of human colorectal cancers.
A method of inhibiting expression of MDM2 in a mammal, the method comprising administering to the mammal an effective MDM2-expression inhibiting amount of an anti-MDM2 antisense oligonucleotide.
A method of inhibiting cancer in vivo, the method comprising administering a cancer-inhibiting amount of an anti-MDM2 antisense oligonucleotide, wherein the cancer involves overexpression of MDM2.
A method of increasing intracellular p53 concentration, the method comprising administering to the cell or to an animal comprising the cell an effective MDM2-expression inhibiting amount of an anti-MDM2 antisense oligonucleotide.
Dependencies are inferred from the claim text.